Results

1–10 of 13 results for Jeffrey S. Heier

ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy
Jeffrey S. Heier, MD
Annual Meeting Talks
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Prospective Longitudinal Study: Fluid Quantification From Daily Self-imaging With Home OCT in Neovascular Age-Related Macular Degeneration
Jeffrey S. Heier, MD
Annual Meeting Talks
2021
Intravitreal AAVCAGsCD59 as Adjunct Anti-VEGF Treatment for Wet Age-Related Macular Degeneration
Jeffrey S. Heier, MD
Annual Meeting Talks
2020
Prospective Longitudinal Study: Fluid Quantification From Daily Self-imaging With Home OCT in Neovascular Age-Related Macular Degeneration (NV-AMD)
Jeffrey S. Heier, MD
Updates from the Field
2021
Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies
Jeffrey S. Heier, MD
Updates from the Field
2020
Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular Age-Related Macular Degeneration in High Risk Eyes
Jeffrey S. Heier, MD
Updates from the Field
2019
Jeffrey Heier Last Word
Jeffrey S. Heier, MD
Annual Meeting Talks
Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019
RGX-314 Gene Therapy Subretinal Delivery for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
Jeffrey S. Heier, MD
Annual Meeting Talks
2017